Genentech announced that its experimental ovarian cancer drug pertuzumab "encouraging" data in a mid-stage trial, but one news report quoted an analyst who claimed the company had confirmed that the trial had not produced statistically significant results. The full range of data will be presented at an upcoming medical gathering. The study collected data on 130 women with advanced ovarian cancer. A news service quoted analyst Jason Kantor who reportedly confirmed that while the data was 'encouraging,' the study did not meet its primary endpoint.
- check out Genentech's press release
- here's the AP report for more